Modulating the gut microbiota to enhance immune checkpoint inhibitor efficacy in colorectal cancer: mechanisms, therapeutic strategies, and clinical perspectives - PubMed
3 hours ago
- #gut microbiota
- #immune checkpoint inhibitors
- #colorectal cancer
- Immune checkpoint inhibitors (ICIs) have limited efficacy in most colorectal cancer (CRC) cases, primarily working only in microsatellite instability-high (MSI-H) tumors.
- The gut microbiota plays a crucial role in regulating ICI response through specific bacterial strains, metabolites, and components like extracellular vesicles.
- Gut microbiome circadian rhythms may enable personalized chrono-immunotherapy to improve treatment timing and effectiveness.
- Microbiota-targeting strategies show promise as adjunctive therapies to overcome ICI resistance and enhance efficacy in CRC.
- Clinical evidence and future perspectives aim to expand the immunotherapy benefits for CRC patients.